SCHEMBL708387

SCHEMBL708387

COc1cc(C(=O)CC(=O)CCc2ccccc2)cc(OC)c1OC

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
HTT P42858 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ALOX5 P09917 3/20 0.57
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 1/20 0.51
SCN5A Q14524 1/20 0.51
SCN2A Q99250 1/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HPGD P15428 1/20 0.49
OR51E2 Q9H255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709246 0.83 TDP1 (0.60) LMNASMN1; SMN2HTTTDP1L3MBTL1
SCHEMBL8816104 0.83 KMT2A (0.56) LMNASMN1; SMN2HTTTDP1L3MBTL1
SCHEMBL969334 0.82 TDP1 (0.59) LMNASMN1; SMN2HTTTDP1L3MBTL1
Hydrochloric Acid SCHEMBL8812982 0.82 KMT2A (0.55) LMNASMN1; SMN2HTTTDP1L3MBTL1
SCHEMBL7823257 0.80 ALDH1A1 (0.61) LMNASMN1; SMN2HTTTDP1L3MBTL1
SCHEMBL8548671 0.79 LMNA (0.51) LMNASMN1; SMN2HTTTDP1L3MBTL1
SCHEMBL8549825 0.79 HPGD (0.61) LMNASMN1; SMN2HTTTDP1L3MBTL1
Hydrochloric Acid SCHEMBL8548328 0.78 HPGD (0.60) LMNASMN1; SMN2HTTTDP1L3MBTL1
SCHEMBL3859999 0.77 TDP1 (0.61) SMN1; SMN2HTTTDP1L3MBTL1KMT2A
SCHEMBL7046987 0.77 ALDH1A1 (0.72) SMN1; SMN2TDP1L3MBTL1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553075-B1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2013-08-14 EP disclosed
EP-2565178-A1 LPA Receptor Antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2013-03-06 EP disclosed
US-20120088782-A1 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-12 US disclosed
US-8124645-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2012-02-28 US disclosed
US-7820682-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-26 US disclosed
US-20100249157-A2 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-30 US disclosed
US-20080293764-A1 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. 2008-11-27 US disclosed
US-20060148830-A1 Lpa receptor antagonist ONO PHARMACEUTICAL CO., LTD. 2006-07-06 US disclosed
EP-1553075-A1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293764-A1 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LMNA 1108/4885SMN1; SMN2 92/4885HTT 2649/4885
US-20100249157-A2 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LMNA 1108/4885SMN1; SMN2 92/4885HTT 2649/4885
US-20120088782-A1 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LMNA 1108/4885SMN1; SMN2 92/4885HTT 2649/4885
US-20060148830-A1 Lpa receptor antagonist LPAR1, LPAR2, LPAR4 LMNA 1108/4885SMN1; SMN2 92/4885HTT 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.